Frontline CLL Therapy: Changes in Paradigm

Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax.

Source: CancerNetwork - February 25, 2017 Category: Cancer & Oncology Authors: Kanti Rai, MD Tags: Hematologic Malignancies Conferences/ICHM 2017 Leukemia & Lymphoma Q Source Type: news